| Year |
Citation |
Score |
| 2020 |
Nazarova L, Rafidi H, Mandikian D, Ferl GZ, Koerber JT, Davies CW, Ulufatu S, Ho J, Lau J, Yu SF, Ernst J, Sadowsky JD, Boswell CA. Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-Length Antibodies. Molecular Cancer Therapeutics. PMID 32024685 DOI: 10.1158/1535-7163.Mct-19-1015 |
0.355 |
|
| 2019 |
Boswell CA, Yadav DB, Mundo EE, Yu SF, Lacap JA, Fourie-O'Donohue A, Kozak KR, Ferl GZ, Zhang C, Ho J, Ulufatu S, Khawli LA, Lin K. Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer. Oncotarget. 10: 6234-6244. PMID 31692898 DOI: 10.18632/Oncotarget.27263 |
0.346 |
|
| 2019 |
Riegler J, Gill H, Ogasawara A, Hedehus M, Javinal V, Oeh J, Ferl GZ, Marik J, Williams S, Sampath D, Schartner J, Carano RAD. VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. Neoplasia (New York, N.Y.). 21: 1036-1050. PMID 31521051 DOI: 10.1016/J.Neo.2019.08.003 |
0.342 |
|
| 2018 |
Mandikian D, Rafidi H, Adhikari P, Venkatraman P, Nazarova L, Fung G, Figueroa I, Ferl GZ, Ulufatu S, Ho J, McCaughey C, Lau J, Yu SF, Prabhu S, Sadowsky J, et al. Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging. Mabs. PMID 30199303 DOI: 10.1080/19420862.2018.1521132 |
0.373 |
|
| 2018 |
Ferl GZ, Reyes A, Sun LL, Cheu M, Oldendorp A, Ramanujan S, Stefanich EG. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clinical and Translational Science. PMID 29351372 DOI: 10.1111/Cts.12535 |
0.318 |
|
| 2015 |
Hsu YH, Huang Z, Ferl GZ, Ng CM. GPU-accelerated compartmental modeling analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Plos One. 10: e0118421. PMID 25786263 DOI: 10.1371/Journal.Pone.0118421 |
0.346 |
|
| 2015 |
Ferl GZ, O'Connor JP, Parker GJ, Carano RA, Acharya SJ, Jayson GC, Port RE. Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab. Journal of Magnetic Resonance Imaging : Jmri. 41: 132-41. PMID 24753433 DOI: 10.1002/Jmri.24514 |
0.315 |
|
| 2013 |
Hsu YH, Ferl GZ, Ng CM. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Magnetic Resonance Imaging. 31: 618-23. PMID 23200680 DOI: 10.1016/J.Mri.2012.09.007 |
0.379 |
|
| 2012 |
Ferl GZ, Port RE. Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data Clinical Pharmacology and Therapeutics. 92: 118-124. PMID 22588603 DOI: 10.1038/Clpt.2012.63 |
0.356 |
|
| 2011 |
Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA. Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. Plos One. 6: e17874. PMID 21436893 DOI: 10.1371/Journal.Pone.0017874 |
0.31 |
|
| 2010 |
Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, Theil FP, Fielder PJ, Khawli LA. Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Molecular Pharmaceutics. 7: 1848-57. PMID 20704296 DOI: 10.1021/Mp100183K |
0.345 |
|
| 2010 |
Ferl GZ, Xu L, Friesenhahn M, Bernstein LJ, Barboriak DP, Port RE. An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine. 63: 1366-75. PMID 20432307 DOI: 10.1002/Mrm.22335 |
0.363 |
|
| 2009 |
Ferl GZ, Dumont RA, Hildebrandt IJ, Armijo A, Haubner R, Reischl G, Su H, Weber WA, Huang SC. Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 250-8. PMID 19164244 DOI: 10.2967/Jnumed.108.054049 |
0.328 |
|
| 2006 |
Ferl GZ, Kenanova V, Wu AM, DiStefano JJ. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Molecular Cancer Therapeutics. 5: 1550-8. PMID 16818514 DOI: 10.1158/1535-7163.Mct-06-0072 |
0.345 |
|
| 2005 |
Ferl GZ, Wu AM, DiStefano JJ. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Annals of Biomedical Engineering. 33: 1640-52. PMID 16341929 DOI: 10.1007/S10439-011-0373-7 |
0.396 |
|
| 2004 |
Guo S, Ferl GZ, Deora R, Riedinger M, Yin S, Kerwin JL, Loo JA, Witte ON. A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation. Proceedings of the National Academy of Sciences of the United States of America. 101: 14180-5. PMID 15375214 DOI: 10.1073/Pnas.0405878101 |
0.44 |
|
| 2003 |
Ferl GZ, Timmerman JM, Witte ON. Extending the utility of gene profiling data by bridging microarray platforms. Proceedings of the National Academy of Sciences of the United States of America. 100: 10585-7. PMID 12963810 DOI: 10.1073/Pnas.2034937100 |
0.447 |
|
| 2002 |
Fruman DA, Ferl GZ, An SS, Donahue AC, Satterthwaite AB, Witte ON. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 99: 359-64. PMID 11756681 DOI: 10.1073/Pnas.012605099 |
0.444 |
|
| Show low-probability matches. |